Corrigendum to "A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients" The Lancet Regional Health-Western Pacific, Volume 55 (2025), 101464

Affiliations

¹ Diabetes, Thyroid and Endocrine Center, Shin Koga Hospital, 120 Tenjin-cho, Kurume, Fukuoka, 830-8577, Japan.
² Kozawa Eye Hospital and Diabetes Center, 246-6 Yoshizawa-cho, Mito-shi, Ibaraki, 310-0845, Japan.
³ Olympia Eye Hospital, 2-18-12 Jinguumae, Shibuya-ku, Tokyo, 150-0001, Japan.
⁴ Department of Oculoplastic, Orbital & Lacrimal Surgery, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan.
⁵ Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
⁶ Hayashi Eye Hospital, 4-23-35 Hakataekimae, Hakata-ku, Fukuoka, 812-0011, Japan.
⁷ Oculoplastic Surgery Center, Department of Ophthalmology, Osaka Kaisei Hospital, 1-6-10 Miyahara, Yodogawa-ku, Osaka, 532-0003, Japan.
⁸ Miyazaki Chuo Eye Hospital, 3-6-21 Shimizu, Miyazaki-shi, Miyazaki, 880-0021, Japan.
⁹ Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320-1799, USA.
¹⁰ Kuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, Kobe, 650-0011, Japan.

Published Erratum

Yuji Hiromatsu et al. Lancet Reg Health West Pac. 2025.

. 2025 Jun 18:60:101607.

doi: 10.1016/j.lanwpc.2025.101607. eCollection 2025 Jul.

¹ Diabetes, Thyroid and Endocrine Center, Shin Koga Hospital, 120 Tenjin-cho, Kurume, Fukuoka, 830-8577, Japan.
² Kozawa Eye Hospital and Diabetes Center, 246-6 Yoshizawa-cho, Mito-shi, Ibaraki, 310-0845, Japan.
³ Olympia Eye Hospital, 2-18-12 Jinguumae, Shibuya-ku, Tokyo, 150-0001, Japan.
⁴ Department of Oculoplastic, Orbital & Lacrimal Surgery, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan.
⁵ Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
⁶ Hayashi Eye Hospital, 4-23-35 Hakataekimae, Hakata-ku, Fukuoka, 812-0011, Japan.
⁷ Oculoplastic Surgery Center, Department of Ophthalmology, Osaka Kaisei Hospital, 1-6-10 Miyahara, Yodogawa-ku, Osaka, 532-0003, Japan.
⁸ Miyazaki Chuo Eye Hospital, 3-6-21 Shimizu, Miyazaki-shi, Miyazaki, 880-0021, Japan.
⁹ Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320-1799, USA.
¹⁰ Kuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, Kobe, 650-0011, Japan.

Abstract

[This corrects the article DOI: 10.1016/j.lanwpc.2025.101464.].

A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients.
Hiromatsu Y, Ishikawa E, Kozaki A, Takahashi Y, Tanabe M, Hayashi K, Imagawa Y, Kaneda K, Mimura M, Dai X, Hayashida T, Akamizu T. Hiromatsu Y, et al. Lancet Reg Health West Pac. 2025 Jan 18;55:101464. doi: 10.1016/j.lanwpc.2025.101464. eCollection 2025 Feb. Lancet Reg Health West Pac. 2025. PMID: 39896230 Free PMC article.